Lilly buys CoLucid for $960mm; gets back its migraine candidate
Eli Lilly & Co. is paying $960mm ($46.50 per share in cash, a 36% premium) to acquire headache pain drug development firm CoLucid Pharmaceuticals Inc.
- Full Acquisition
- Includes Contract
- Payment Includes Cash
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.